Compare NSP & AUPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NSP | AUPH |
|---|---|---|
| Founded | 1986 | 1993 |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Professional Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.7B | 1.6B |
| IPO Year | 1997 | 1999 |
| Metric | NSP | AUPH |
|---|---|---|
| Price | $38.55 | $15.78 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 3 | 4 |
| Target Price | ★ $47.67 | $17.25 |
| AVG Volume (30 Days) | 910.8K | ★ 1.6M |
| Earning Date | 11-03-2025 | 11-04-2025 |
| Dividend Yield | ★ 6.24% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | 0.45 | ★ 0.55 |
| Revenue | ★ $6,757,000,000.00 | $265,808,000.00 |
| Revenue This Year | $4.71 | $21.22 |
| Revenue Next Year | $6.40 | $15.40 |
| P/E Ratio | $85.99 | ★ $28.81 |
| Revenue Growth | 3.19 | ★ 20.62 |
| 52 Week Low | $31.00 | $6.55 |
| 52 Week High | $95.98 | $16.48 |
| Indicator | NSP | AUPH |
|---|---|---|
| Relative Strength Index (RSI) | 57.67 | 59.93 |
| Support Level | $34.14 | $15.15 |
| Resistance Level | $36.32 | $16.03 |
| Average True Range (ATR) | 1.32 | 0.50 |
| MACD | 0.84 | -0.13 |
| Stochastic Oscillator | 90.83 | 64.33 |
Insperity Inc is a company that provides a wide range of human resources and business solutions designed to help businesses improve their performance. Small and midsize enterprises are the company's primary target customers. Majority of the company's products are offered through the company's Workforce Optimization and Workforce Synchronization solutions, which comprise various human resource functions, such as payroll and employment administration, employee benefits and compensation, government compliance, performance management, training and development services, and human capital management. The company generates all of its revenue in the United States.
Aurinia Pharmaceuticals Inc is a biopharmaceutical company focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs. The company developed LUPKYNIS (voclosporin), the first FDA-approved oral therapy for the treatment of adult patients with active lupus nephritis. It is also developing AUR200, a dual inhibitor of B cell activating factor (BAFF) and a proliferation-inducing ligand (APRIL), for the potential treatment of autoimmune diseases.